|
23 Feb |
Coya Therapeutics™ Announces Formation of Scientific Advisory Board |
|
17 Feb |
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing |
|
02 Feb |
Gain Therapeutics Strengthens Leadership Team with the Appointment of Four Industry Leaders to Its Board of Directors |
|
21 Jan |
INmune Bio, Inc. Announces XPro1595 Found to Decrease Neuroinflammation and Neurodegeneration Biomarkers in Patients with Alzheimer’s Disease in Phase 1b Trial |
|
19 Jan |
Allele Capital Partners is pleased to announce that Ankit Bhargava, MD has joined the firm as Managing Director |
|
11 Jan |
Daré Bioscience Announces Positive Topline Results From DARE-BVFREE, a Phase 3 Trial of DARE-BV1 in Patients Diagnosed with Bacterial Vaginosis |
|
16 Dec |
NeuBase Therapeutics Announces Positive Preclinical In Vivo Data for PATrOL™-enabled Anti-gene for the Treatment of Myotonic Dystrophy Type 1 |
|
02 Dec |
NeuBase Therapeutics Announces Appointment of Curt Bradshaw, Ph.D. as Chief Scientific Officer |
|
30 Nov |
Gain Therapeutics and University of Maryland School of Medicine Announce Research Collaboration |
|
25 Nov |
Invo Bioscience and Idsmed Group Enter Distribution Agreement for Malaysia |
|
18 Nov |
Invo Bioscience Forms Scientific Advisory Board with Leaders from Fertility Industry |
|
10 Sep |
Gain Therapeutics Announces Research Collaboration with Sumitomo Dainippon Pharma Co., Ltd to Advance Gain’s Lysosomal Enzyme Allosteric Regulator Program |
|
08 Sep |
NeuBase: Gene Therapy Crosses a Digital Divide |
|
08 Sep |
Journal of Neuroinflammation: IC 100 is ZyVersa Therapeutics’ Lead Anti-inflammatory Candidate in Development for Numerous Inflammatory Conditions |
|
21 Jul |
Gain Therapeutics, Inc. Announces Closing of $10 Million Series B Financing |
|
28 Apr |
NeuBase Therapeutics Announces Pricing of $31.5 Million Public Offering of Common Stock |
|
24 Feb |
Allele Capital Partners is pleased to announce that Tom Masterson and Dave Marston have joined the firm |
|
02 Dec |
NeuBase Therapeutics Wins The Scientist’s Top 10 Innovations of 2019 Award for its Janus Base Technology |
|
10 Sep |
ZyVersa Therapeutics Recognized By Business Worldwide as 20 Most Innovative Companies to Watch 2019 Winner |
|
19 Aug |
NeuBase Therapeutics featured August 1st in BioCentury “NeuBase takes antisense oligos to more targets in more places” |
|
19 Aug |
ZyVersa Therapeutics featured in August 15th BioCentury “Biotechs Explore the Next Generation of Inflammasome Targets, with Caution” |
|
12 Jul |
Allele Capital Partners serves as Investor and Advisor to NeuBase Therapeutics in its financings and merger onto NASDAQ through Ohr Pharmaceutical |
|
03 Jun |
Allele Capital Partners is pleased to announce that Matt Hughes has joined as Managing Director of Corporate Advisory Services. |
|
21 May |
ZyVersa Therapeutics Appoints Inaugural Immunology Scientific Advisory Board For Its Inflammasome Technology Platform |
|
16 May |
ZyVersa Therapeutics Enhances Scientific Advisory Board with Three Esteemed Nephrologists |
|
16 May |
NeuBase Therapeutics Designates Industry Leaders to Board of Directors |
|
01 May |
Variant Pharmaceuticals Has a New Name - ZyVersa Therapeutics, Inc. |
|
22 Apr |
Variant Pharmaceuticals Expands Development Focus Into $60+ Billion Anti-inflammatory Market with Worldwide License to Novel Inflammasome Inhibitor |
|
11 Mar |
NeuBase Therapeutics Announces Agreements for $9 Million Financing to Support Advancement of its Proprietary PATrOL(tm) Platform |
|
21 Jan |
Allele Capital Partners acts as Financial Advisor to NeuBase Therapeutics, Inc. in its merger agreement with Ohr Pharmaceutical, Inc. (NASDAQ: OHRP) |
|
03 Dec |
Variant Pharmaceuticals Secures $10 Million in Financing from Korean Company, Incon Co., Ltd. |
|
30 May |
TherapeuticsMD (TXMD) Announces FDA Approval of TX-004HR: IMVEXXY (estradiol vaginal inserts) |
|
16 Apr |
Allele Capital Partners serves as Financial Advisor for PolarityTE’s (NASDAQ: COOL) $37.3 million public offering. |
Allele partners and employees publish occasional articles and present at industry conferences. To receive these materials, which describe our approach to drug and medical device development and commercialization, how we capitalize these activities and the companies that conduct them, subscribe to our news feed.